8-K: Vaxart Secures Additional Funding and Initiates Sentinel Cohort for Phase 2b COVID-19 Vaccine Trial

Vaxart has received increased funding and commenced the sentinel phase of its Phase 2b trial for an oral COVID-19 vaccine, comparing it to an approved mRNA vaccine.

Summary

• Vaxart has entered into a modification of its agreement with Advanced Technology International, increasing the total potential funding to approximately $456.1 million.
• The modification also increases the funding allocated to the Phase 2b trial to approximately $96.5 million.
• A portion of the additional funding will be used to manufacture a vaccine construct targeting the KP.2 strain.
• The company has initiated the sentinel cohort of its Phase 2b trial, which will involve 400 participants.
• The sentinel cohort will compare Vaxart's oral XBB COVID-19 vaccine against an approved mRNA vaccine.
• The full Phase 2b trial aims to enroll 10,000 participants after the sentinel cohort's safety data is reviewed.
• The trial will measure efficacy for symptomatic and asymptomatic disease, immune response, and adverse events.
• The primary endpoint is the relative efficacy of Vaxart's vaccine compared to the mRNA comparator in preventing symptomatic disease.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with increased funding and the initiation of a key clinical trial phase, but also acknowledges the inherent risks in drug development.

Positives

• The increase in funding provides additional resources for the development of Vaxart's oral COVID-19 vaccine.
• The initiation of the sentinel cohort is a significant step forward in the Phase 2b trial.
• The trial will directly compare Vaxart's oral vaccine to an approved mRNA vaccine, providing valuable data.
• The trial will measure both symptomatic and asymptomatic disease, providing a comprehensive assessment of efficacy.
• The inclusion of a large number of participants in the full trial (10,000) will provide robust data.

Risks

• The company's ability to achieve milestones and deliverables under the Project Agreement is subject to risk.
• The company is subject to risks associated with achieving successful results in the Trial.
• The company has continuing operating losses.
• There are risks and uncertainties associated with clinical and regulatory development plans.
• There are risks associated with the timing of funding pursuant to the Project Agreement.
• There are risks associated with the structure, design, and objectives of the Trial.

Future Outlook

The company expects to continue the Phase 2b trial, including the enrollment of 10,000 participants after the sentinel cohort's safety review, and anticipates reporting results from the trial.

Management Comments

• Dr. James F. Cummings, Vaxart's Chief Medical Officer, stated that initiating the sentinel cohort is a strong step toward developing a sustainable solution to the threat of COVID-19.
• Dr. Cummings also mentioned that they are progressing toward their goal of conducting the Phase 2b study and look forward to the results of their mucosal technology's first head-to-head comparison against an approved mRNA vaccine.

Industry Context

This announcement is significant in the context of the ongoing global effort to develop more effective and accessible COVID-19 vaccines. Vaxart's oral vaccine approach is a novel alternative to traditional injectable vaccines, potentially offering advantages in terms of ease of administration and distribution.

Comparison to Industry Standards

• The Phase 2b trial design, comparing Vaxart's oral vaccine to an approved mRNA vaccine, aligns with industry standards for evaluating vaccine efficacy.
• The trial's focus on both symptomatic and asymptomatic disease is comprehensive and reflects current best practices in vaccine research.
• The large sample size of 10,000 participants in the full trial is comparable to other large-scale vaccine trials.
• Companies like Moderna and Pfizer have set the benchmark for mRNA vaccine development, and Vaxart's trial will provide a direct comparison to these established technologies.
• The use of a Data and Safety Monitoring Board (DSMB) is a standard practice in clinical trials to ensure participant safety.

Stakeholder Impact

• Shareholders may view the increased funding and trial progress positively.
• Employees may be impacted by the increased workload associated with the trial.
• Customers (potential vaccine recipients) may benefit from the development of a new vaccine option.
• Suppliers may see increased demand for materials related to vaccine production.
• Creditors may view the increased funding as a positive sign of the company's financial stability.

Next Steps

• The company will continue the sentinel cohort of the Phase 2b trial.
• The company will submit the 30-day safety data of the 400 participants to an independent Data and Safety Monitoring Board (DSMB) and the FDA.
• The company will proceed to enroll 10,000 participants in the second part of the trial after the safety review.
• The company will perform a primary efficacy analysis when all participants have either discontinued or completed a study visit 12 months post-vaccination.

Key Dates

Keywords

COVID-19 vaccine, oral vaccine, Phase 2b trial, mRNA vaccine, clinical trial, BARDA, Project NextGen, immunogenicity, efficacy, sentinel cohort